Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).

Erkinjuntti, T; Gauthier, S; Bullock, R; Kurz, A; Hammond, G; Schwalen, S; Zhu, Y; Brashear, R

Erkinjuntti, T; Gauthier, S; Bullock, R; Kurz, A; Hammond, G; Schwalen, S; Zhu, Y; Brashear, R.

Affiliation

Erkinjuntti T; Memory Research Unit, Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.

J Psychopharmacol ; 22(7): 761-8, 2008 Sep.

Article in En | MEDLINE | ID: mdl-18308781

Subject(s)

Alzheimer Disease/drug therapy; Cerebrovascular Disorders/drug therapy; Galantamine/therapeutic use; Nootropic Agents/therapeutic use; Activities of Daily Living; Aged; Alzheimer Disease/complications; Alzheimer Disease/psychology; Cerebrovascular Disorders/complications; Cerebrovascular Disorders/psychology; Cognition/drug effects; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Galantamine/adverse effects; Humans; Male; Nootropic Agents/adverse effects; Psychomotor Performance/drug effects; Risk Assessment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cerebrovascular Disorders / Nootropic Agents / Alzheimer Disease / Galantamine Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: J Psychopharmacol Journal subject: PSICOFARMACOLOGIA Year: 2008 Document type: Article Affiliation country: Finland Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google